Benzonaphthyridine

Benzonaphthyridine

SCHEMBL30897319

c1ccc2c(c1)nnc1ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR3 P46089 3/20 1.00
LMNA P02545 3/20 0.48
HTT P42858 2/20 0.48
KDM4E B2RXH2 6/20 0.48
MAPT P10636 3/20 0.47
LCK P06239 1/20 0.46
MAP2K3 P46734 1/20 0.46
MAP2K6 P52564 1/20 0.46
BTK Q06187 1/20 0.46
MAP3K19 Q56UN5 1/20 0.46
NEK10 Q6ZWH5 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C19 P33261 1/20 0.46
ALDH1A1 P00352 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
MAOA P21397 2/20 0.46
GLA P06280 2/20 0.46
HPGD P15428 2/20 0.46
CASP1 P29466 2/20 0.46
CASP7 P55210 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzonaphthyridine SCHEMBL29600756 1.00 GPR3 (1.00) GPR3LMNAHTTKDM4EMAPT
Benzonaphthyridine SCHEMBL51197 1.00 GPR3 (1.00) GPR3LMNAHTTKDM4EMAPT
SCHEMBL4485428 0.93 GPR3 (0.87) GPR3LMNAHTTKDM4EMAPT
Benzonaphthyridine SCHEMBL38660425 0.84 GPR3 (0.70) GPR3LMNAHTTKDM4ELCK
SCHEMBL1179339 0.82 GPR3 (0.67) GPR3LMNAHTTKDM4ELCK
SCHEMBL11195652 0.80 GPR3 (0.64) GPR3LMNAHTTKDM4EMAPT
SCHEMBL7052017 0.80 GPR3 (0.64) GPR3LMNAHTTKDM4EMAPT
SCHEMBL11203305 0.80 GPR3 (0.64) GPR3LMNAHTTKDM4EMAPT
SCHEMBL5478388 0.80 GPR3 (0.64) GPR3LMNAKDM4EMAPTCYP1A2
SCHEMBL11198396 0.80 GPR3 (0.64) GPR3LMNAHTTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250339551-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) 2025-11-06 US disclosed
EP-4604992-A1 VACCINE GlaxoSmithKline Biologicals SA (BE) 2025-08-27 EP disclosed
EP-3773549-B1 COMBINATION OF QUINOLINE-4-CARBOXAMIDES AND BENZONAPHTHYRIDINE DERIVATIVES AS ANTIMALARIAL DRUG COMBINATION MERCK PATENT GMBH (DE) 2024-08-28 EP disclosed
WO-2024083873-A1 VACCINE GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2024-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250339551-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES FCGR2A, FCGR3B, FCGR1A GPR3 2363/4885LMNA 4284/4885HTT 2413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.